MAPK3 and thyroid cancer: Comparably, pharmacological inhibition of BRAF or ERK1/2 also significantly down-regulated USP15 expressions in BRAFV600E-mutated human thyroid cancer cells (Fig. 4b and Supplementary Fig. 3a).